Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,026 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS.
Bushnell SE, Zhao Z, Stebbins CC, Cadavid D, Buko AM, Whalley ET, Davis JA, Versage EM, Richert JR, Axtell RC, Steinman L, Medori R. Bushnell SE, et al. Among authors: davis ja. Neurology. 2012 Aug 7;79(6):531-7. doi: 10.1212/WNL.0b013e318259e123. Epub 2012 May 9. Neurology. 2012. PMID: 22573631 Free PMC article.
Familial megalencephaly or hydrocephalus?
Schreier H, Rapin I, Davis J. Schreier H, et al. Neurology. 1974 Mar;24(3):232-6. doi: 10.1212/wnl.24.3.232. Neurology. 1974. PMID: 4855950 No abstract available.
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium.
Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, Dima D, Freeman CL, Puglianini OC, Kocoglu MH, Atrash S, Voorhees PM, Shune L, McGuirk JP, Simmons G, Sborov DW, Davis JA, Kaur G, Sannareddy A, Ferreri CJ, Gaballa MR, Goldsmith S, Nadeem O, Midha S, Wagner CB, Locke FL, Patel KK, Khouri J, Anderson LD Jr, Lin Y. Afrough A, et al. Among authors: davis ja. Blood Cancer J. 2024 Apr 12;14(1):63. doi: 10.1038/s41408-024-00993-0. Blood Cancer J. 2024. PMID: 38609386 Free PMC article. No abstract available.
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor.
Fiskus W, Piel J, Collins MP, Hentemann M, Cuglievan B, Mill CP, Birdwell C, Das K, Davis JA, Hou H, Jain A, Malovannaya A, Kadia TM, Daver NG, Sasaki K, Takahashi K, Hammond D, Reville PK, Wang J, Loghavi S, Sen R, Ruan X, Su X, Flores L, DiNardo CD, Bhalla KN. Fiskus W, et al. Among authors: davis ja. Blood. 2024 Feb 16:blood.2023022832. doi: 10.1182/blood.2023022832. Online ahead of print. Blood. 2024. PMID: 38437498
1,026 results